Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has bee...

Descripción completa

Detalles Bibliográficos
Autor principal: AlDallal, Salma M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530057/
https://www.ncbi.nlm.nih.gov/pubmed/28790834
http://dx.doi.org/10.2147/TCRM.S140023
_version_ 1783253211279261696
author AlDallal, Salma M
author_facet AlDallal, Salma M
author_sort AlDallal, Salma M
collection PubMed
description Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia.
format Online
Article
Text
id pubmed-5530057
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55300572017-08-08 Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients AlDallal, Salma M Ther Clin Risk Manag Review Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia. Dove Medical Press 2017-07-20 /pmc/articles/PMC5530057/ /pubmed/28790834 http://dx.doi.org/10.2147/TCRM.S140023 Text en © 2017 AlDallal. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
AlDallal, Salma M
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title_full Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title_fullStr Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title_full_unstemmed Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title_short Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
title_sort ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530057/
https://www.ncbi.nlm.nih.gov/pubmed/28790834
http://dx.doi.org/10.2147/TCRM.S140023
work_keys_str_mv AT aldallalsalmam ofatumumabavalidtreatmentoptionforchroniclymphocyticleukemiapatients

Ejemplares similares